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Abstract
Kainate-induced epilepsy has been shown to be associated
with increased levels of neuropeptide Y (NPY) in the rat hip-
pocampus. However, there is no information on how increased
levels of this peptide might modulate excitation in kainate-
induced epilepsy. In this work, we investigated the modulation
of glutamate release by NPY receptors in hippocampal syna-
ptosomes isolated from epileptic rats. In the acute phase of
epilepsy, a transient decrease in the efficiency of NPY and
selective NPY receptor agonists in inhibiting glutamate release
was observed. Moreover, in the chronic epileptic hippocampus,
a decrease in the efficiency of NPY and the Y2 receptor agonist,
NPY13-36, was also found. Simultaneously, we observed that
the epileptic hippocampus expresses higher levels of NPY,
which may account for an increased basal inhibition of glu-
tamate release. Consistently, the blockade of Y2 receptors
increased KCl-evoked glutamate release, and there was an
increase in Y2 receptor mRNA levels 30 days after kainic acid
injection, suggesting a basal effect of NPY through Y2 recep-
tors. Taken together, these results indicate that an increased
function of the NPY modulatory system in the epileptic hippo-
campus may contribute to basal inhibition of glutamate release
and control hyperexcitability.
Keywords: epilepsy, glutamate, hippocampus, neuropeptide
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Changes in the expression of various neuropeptides have
been observed in different models of temporal lobe epilepsy
(Bellmann et al. 1991; Schwarzer et al. 1995) and the
hippocampus has attracted particular interest due to its
central role in limbic epilepsy (Ben-Ari 1985). Neuropeptide
Y (NPY), a 36 amino acid peptide, is one of the most
abundant and widely distributed neuropeptides in the central
and peripheral nervous systems. It modulates numerous
physiological processes including memory, anxiety, seizures
and feeding behaviour (Michel et al. 1998). Central admin-
istration of NPY decreases pharmacologically- and electric-
ally-evoked seizures (Smialowska et al. 1996; Woldbye
et al. 1996, 1997), and transgenic mice lacking endogenous
NPY exhibit increased sensitivity to seizure induction
(Baraban et al. 1997). Moreover, the role of endogenous
NPY in regulating seizure activity is supported by evidence
of increased NPY levels under epileptic conditions in both
inhibitory interneurones and in excitatory granule cells that,
in control conditions, do not contain the peptide (Vezzani
et al. 1999, 2002). Park and collaborators (2001) also
observed an increase in the number of NPY-positive
neurones, and that these neurones are resistant to kainate-
induced seizures in the whole hippocampus. More recently,
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others (Richichi et al. 2004) showed that long-lasting NPY
expression in the rat hippocampus, using a recombinant
adeno-associated viral vector, reduced electroencephalogram
(EEG) seizures and delayed seizure onset markedly.
Seizure-related increase in NPY expression is accompan-
ied by modified levels of NPY receptor subtypes in the
hippocampus (Kofler et al. 1997; Gobbi et al. 1998;
Schwarzer et al. 1998; Vezzani et al. 2000), and it seems
that more than one receptor subtype could be responsible for
mediating the anti-epileptic effects of NPY. This peptide
inhibits excitatory neurotransmission and reduces glutamate
release by acting mainly on presynaptic Y2 receptors (Greber
et al. 1994; Silva et al. 2001, 2003a). Indeed, electro-
physiological and pharmacological studies have revealed
that NPY acts predominantly through Y2 receptors (Weiser
et al. 2000; Silva et al. 2003a) and inhibits glutamate release
by reducing Ca2+ influx (Schwarzer et al. 1998; Silva et al.
2001, 2003a). Moreover, the increase in Y2 receptor binding
in the hilus of the dentate gyrus is associated with enhanced
release of NPY after kainate injection (Ro¨der et al. 1996).
The involvement of the Y1 receptor subtype is not so clear,
but previous studies have shown that these receptors also
inhibit Ca2+ influx and glutamate release in the dentate gyrus
(McQuiston et al. 1996) and CA3 hippocampal subregions,
as well as in total hippocampus (Silva et al. 2001, 2003a).
The pharmacological profile of centrally administered NPY
analogues capable of inhibiting kainate-induced seizures and
hippocampal excitability in rats also suggests the involve-
ment, at least in part, of Y5 receptors (Woldbye et al. 1997;
Reibel et al. 2001). Indeed, using Y5R-deficient mice, Marsh
et al. (1999) demonstrated that these mice do not exhibit
spontaneous seizure-like activity.
Accumulating evidence clearly suggests that seizure
activity increases the expression of NPY and NPY receptors.
In the present work, we have identified a role for NPY
receptors in modulating glutamate release and the variation
of NPY levels under epileptic conditions. Moreover, we also
suggest that endogenous NPY contributes to basal inhibition
of glutamate release in synaptosomes isolated from the
epileptic rat hippocampus.
Materials and methods
Kainate treatment
Male 6-week-old Wistar rats (150–200 g) were injected intraperiton-
eally with kainic acid (KA) (Sigma, St Louis, MO, USA; 10 mg/kg
body weight) dissolved in a maximum volume of 500 lL sterile 0.9%
NaCl, and a control group of animals were injected with the same
volume of saline. Rats were observed for at least 3 h and their
behaviour was rated as described previously (Sperk et al. 1983). All
the animals used in the present study achieved status epilepticus and
were killed 6 h, 24 h, 72 h and 30 days after KA injection.
All procedures involving experimental animals were performed
in accordance with European Community guidelines. All efforts
were made to minimize animal suffering and to reduce the number
of animals used.
Isolation of rat hippocampal synaptosomes
A partially purified synaptosomal fraction (P2) was isolated from
hippocampi or from hippocampal subregions (CA1, CA3 and
dentate gyrus-DG) of male Wistar control or epileptic rats (killed
6 h, 24 h, 72 h and 30 days after KA injection), essentially as
described previously for brain cortex (McMahon et al. 1992) with
some modifications (Malva et al. 1996; Silva et al. 2001). The
hippocampi were homogenized in 0.32 M sucrose, 10 mM HEPES-
Na, pH 7.4, using a Thomas B-Potter homogenizer (Thomas
Scientific, Swedesboro, NJ, USA), and centrifuged at 3000 g for
2 min. The pellet obtained was resuspended, followed by sedimen-
tation at the same speed. The combined supernatant fluids were spun
for 12 min at 14 600 g and a P2 pellet was obtained. The upper,
whiter layer of the pellet, containing synaptosomes (Whittaker
1984), was removed with a small spoon and resuspended in the
same sucrose medium as that used before.
Coronal slices of hippocampus (800 lm thick) were prepared for
the isolation of synaptosomes from hippocampal subregions (CA1,
CA3 and DG) of non-epileptic and epileptic rats (24 h and 30 days
after KA injection). In each slice, the fimbria and the subiculum
were separated from the rest of the slice under stereomicroscopic
observation. CA3 subslices were obtained by separation from CA1
and dentate gyrus, and the last separation (CA1 from DG) was
performed through the hippocampal sulcus (Silva et al. 2001). The
pooled subslices were homogenized in the sucrose medium using a
Thomas AA-Potter homogenizer, transferred to Eppendorf tubes and
centrifuged as described for the isolation of whole hippocampal
synaptosomes. The protein concentration was determined by the
Biuret method (Layne 1957) for glutamate release experiments, and
the synaptosomes were stored as drained pellets containing 1 mg
protein. For assessing the NPY content, protein concentration was
determined by the bicinchoninic acid (BCA) method (Smith et al.
1985).
Isolation of total RNA from rat hippocampus
Total RNAwas isolated from rat hippocampus using TRI REAGENT
(Sigma) according to manufacturer’s instructions. Briefly, tissue was
homogenized in guanidium thiocyanate and phenol. After adding
chloroform and centrifuging, the RNA was isolated in the aqueous
phase. The RNA was precipitated with isopropanol, the RNA pellet
washed with 75% ethanol and the pellet redissolved in diethylpyro-
carbonate (DEPC)-treated water.
The total amount of RNAwas quantified by optical density (OD)
measurements at 260 nm, and the purity was evaluated by
measuring the ratio of OD at 260 and 280 nm (RNA/DNA
calculator GeneQuant II, Pharmacia Biotech Amersham Biosciences
AB, Uppsala, Sweden).
Measurement of glutamate release
The release of endogenous glutamate was followed using a
continuous fluorimetric assay as previously described (Nicholls
et al. 1987) with some modifications (Malva et al. 1996; Silva et al.
2001). Synaptosomes (1 mg protein) were pre-incubated for 20 min
at 37C in the following medium (in mM): 132 NaCl, 1 KCl, 1
MgCl2, 1.2 H3PO4, 0.1 CaCl2, 10 glucose, 10 HEPES-Na, pH 7.4,
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with 0.1% fatty acid-free bovine serum albumin (BSA). After this
period, NPY or Y1, Y2 or Y5 receptor agonists {[Leu
31, Pro34]NPY,
NPY13-36 or NPY (19–23)-(Gly1, Ser3, Gln4, Thr6, Ala31, Aib32,
Gln34)-PP, respectively; Bachem, Bubendorf, Switzerland} or
antagonist [BIBP3226 (Peninsula Laboratories, Belmont, CA,
USA), BIIE0246 (provided by Dr Henri Doods, Boehringer
Ingelheim Pharma KG, Germany) and L-152 804 (Tocris, Bristol,
UK), respectively] were added to the incubation medium for an
additional 10 min. Synaptosomes were then centrifuged at 15 800 g
and resuspended in 1 mL of the same medium but without BSA and
with 1 mM CaCl2. The suspension was transferred to a stirred acrylic
cuvette maintained at 37C, followed by the addition of 1 mM
NADP+, 50 U purified glutamate dehydrogenase and again, NPY
receptor agonists or antagonists. Fluorescence was measured using a
Perkin Elmer model LS-5B luminescence spectrometer (Perkin-
Elmer Ltd, Beaconfield, Buckinghamshire, UK) at the excitation and
emission wavelengths of 340 and 460 nm, respectively, with
excitation and emission slits of 5 and 10 nm, respectively. The data
were collected at 0.5 s intervals and at the end of each experiment,
2.5 nM L-glutamate were added as a callibration to allow the
quantification of released glutamate.
Glutamate release was monitored for 11 min and synaptosomes
were stimulated 4 min after the beginning of each experiment with
15 mM KCl.
NPY assay
To determine NPY levels in nerve terminals from hippocampal
subregions (CA1, CA3 and DG) obtained from control and epileptic
rats (killed 24 h and 30 days after KA injection), synaptosomal P2
pellets were resuspended in 350 lL (CA1) or 200 lL (DG, CA3) of
the following medium (in mM): 132 NaCl, 1 KCl, 1 MgCl2, 1.2
H3PO4, 1 CaCl2, 10 glucose, 10 HEPES-Na, pH 7.4. The
suspension of synaptosomes was then centrifuged at 14 600 g for
12 min at 4C, and the pellets were frozen at )20C. Each pellet
was resuspended in 250 lL Krebs buffer (50 mM EDTA, 0.08%
Tween 20) and 10 lL of this preparation were used to quantify NPY
levels. An ELISA system and two antibodies (NPY02 and NPY05)
recognizing distinct epitopes of NPY were used as described
previously (Grouzmann et al. 1992) with some modifications
(Cavadas et al. 2001). This assay measures amidated biologically-
active NPY. A 96-well plate (Polysorp; Nunc, Naperville, IL, USA)
was coated with 200 ng NPY02 diluted in Tris buffer 50 mM,
pH 7.5, overnight at 4C. The plate was washed three times with
Tris-Tween buffer (Tris 50 mM, pH 7.5, with 0.08% Tween 20), and
200 lL 5% low-fat milk in Tris-Tween buffer were added for
30 min. The plate was washed four times with Tris-Tween buffer
and the NPY standards and samples (100 lL of final volume) were
then added overnight at room temperature with slow agitation. Then,
after four washes with Tris-Tween buffer, the second antibody,
NPY05, conjugated with alkaline phosphatase diluted (1 : 2500) in
5% low-fat milk in Tris-Tween buffer (7 h at room temperature, with
slow agitation), was added. After washing twice with Tris buffer
containing 0.25% Tween 20 and twice with Tris buffer containing
0.88% NaCl (w/v), 50 lL of substrate (NADPH solution from the
ELISA amplification kit; Invitrogen Life Technologies, Carlsbad,
CA, USA) was added. After 40 min of incubation, 50 lL of
amplifier (ethanol dehydrogenase mixed with diaphorase from the
ELISA amplification kit) was added and the OD measured at
492 nm using an ELISA render (spectra II, SLT lab instruments,
Salzburg, Austria). The detection limit was 0.25 pM.
RT-PCR analyses
NPY Y2 mRNA expression was determined by reverse transcrip-
tion-PCR (RT-PCR). First, cDNA was transcribed from 2 lg RNA
using avianmicroblastosis virus (AMV) and anOligo-p(dT)15 primer.
PCR was performed in a 100 lL reaction system (Roche Molecular
Biochemicals, Indianapolis, IN, USA) containing 3 lL template
cDNA, 2 lL deoxynucleotide mix, 10 lL 10 · buffer, 2 lL
upstream and 2 lL downstream primer, a variable volume of water
and 0.5 lLTaqDNA polymerase (35 cycles: at 95C for 60 s, at 55C
for 60 s and at 72C for 60 s) (Amersham Biosciences, Amersham,
UK). Primers used in PCR reactions were as follows: NPY Y2,
forward primer 5¢-CTCCAAGCAAATCAGCTTCC-3¢ and the
reverse primer 5¢-GTTTTGTGCCTTCGCTGATGG-3¢; b-actin,
upstream primer 5¢-GACTACCTCATGAAGATCCT-3¢ and the
downstream primer 5¢-ATCTTGATCATGGTGCTG-3¢ (MWG-Bio-
tech AG, Ebersberg, Germany).
PCR products of each sample were subjected to electrophoresis in
a 1.5% agarose gel and stained with ethidium bromide. Densito-
metrical analysis was performed on Versa-Doc Imaging System
(Model 3000, Bio-Rad Laboratories, Hercules, CA, USA) and
mRNA expression was evaluated by the band-intensity ratio of
control versus epileptic rats (% of control).
Statistical analysis
The data are expressed as means ± SEM. Statistics were performed
using one-way ANOVA, followed by Dunnett’s or Bonferroni’s post-
tests, as indicated in the figure legends.
Results
Characterization of the modulation of glutamate release
by NPY receptors in hippocampal synaptosomes obtained
from control versus epileptic rats
Recently, we showed that NPY (1 lM) inhibited 15 mM KCl-
evoked glutamate release from non-epileptic rat hippocampal
synaptosomes (48.2 ± 2.2% of control); total glutamate
release in control conditions was 1.1 ± 0.1 nM glutamate/
mg protein/min while in the presence of 1 lM NPY, it was
0.60 ± 0.1 nM glutamate/mg protein/min (Silva et al. 2003a)
(Fig. 1a). Also, the selective activation of Y1, Y2 or Y5
receptors using 1 lM [Leu31, Pro34]NPY, 300 nM NPY13-36
or 1 lM NPY (19–23)-(Gly1, Ser3, Gln4, Thr6, Ala31, Aib32,
Gln34)-PP, respectively, inhibited glutamate release to
71.6 ± 1.8% (Fig. 1b), 60.1 ± 2.1% (Fig. 1c) or
68.2 ± 2.5% (Fig. 1d), respectively; these inhibitory effects
were prevented by selective NPY receptor antagonists (Silva
et al. 2001, 2003a). In the present work, we showed that the
efficiency of the NPY receptor-mediated inhibition of KCl-
induced release of glutamate from hippocampal synapto-
somes isolated from epileptic rats depends on the stage of the
epileptogenic process.
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In hippocampal synaptosomes prepared from epileptic rats
6 h after KA injection, the activation of Y1 receptors with
1 lM [Leu31, Pro34]NPY inhibited the release of glutamate
(79.3 ± 1.9% of control) (Fig. 1b). However, Y1 receptor-
mediated inhibition of glutamate release was lost 24 h post-
injection (97.8 ± 1.8% of control) and at 72 h or 30 days, the
inhibitory effect have been recovered (56.9 ± 2.5% and
79.0 ± 2.5% of control) (Fig. 1b).
The activation of Y2 receptors with 300 nM NPY 13–36 in
synaptosomes obtained from the hippocampus of epileptic
rats led to a transient loss of Y2 receptor-mediated inhibition
of glutamate release 6 h post-injection, followed by recovery
at 24 h and 72 h post-injection, and again, a loss of Y2
receptor-mediated inhibition of glutamate release 30 days
post-injection. In the presence of 300 nM NPY13-36, KCl-
induced release of glutamate was 60.1 ± 2.1% in non-
epileptic animals and 93.4 ± 3.3%, 68.6 ± 1.4%,
57.2 ± 1.0% or 79.0 ± 3.3% in hippocampal synaptosomes
prepared 6 h, 24 h, 72 h or 30 days post-injection with KA
(Fig. 1c).
The activation of Y5 receptors in epileptic rats 6 h after KA
injection with 1 lM NPY (19–23)-(Gly1, Ser3, Gln4, Thr6,
Ala31, Aib32, Gln34)-PP inhibited glutamate release to
77.4 ± 2.2% of control (Fig. 1d). However, 24 h after KA
injection the efficiency of the Y5 receptors in inhibiting the
release of glutamate decreased (93.0 ± 3.6% of control). The
inhibitory modulation of glutamate release in the presence of
Y5 receptor agonist was recovered 72 h and 30 days after KA
injection, decreasing to levels above control (55.3 ± 2.3% and
53.0 ± 2.0% of control, respectively) (Fig. 1d).
Interestingly, the use of the endogenous agonist, NPY
(1 lM) (Fig. 1a), revealed a pharmacological profile very
similar to that mediated by the activation of Y2 receptors
alone (Fig. 1c). In agreement, in rats killed 6 h after KA
injection, the inhibitory effect of NPY on glutamate release
was abolished (94.1 ± 3.3% of control) but recovered 24 h
and 72 h after KA injection (62.0 ± 1.4% and 54.7 ± 2.5%
of control) (Fig. 1a). Thirty days after KA injection the
inhibition of glutamate release was again less efficient
(71.5 ± 2.5% of control) (Fig. 1a). All the absolute values of
KCl-evoked glutamate release in the presence of the Y1, Y2,
Y5 receptor agonists or NPY obtained in the previously
described experiment are summarized in table 1.
Since NPY and NPY receptors seem to be involved in
other factors unrelated to epilepsy, such as stress, we
performed some further control experiments. Modulation of
glutamate release by NPY13-36 and NPY was observed in
synaptosomes obtained from rats injected with saline (0.9%
NaCl) and killed 6 h or 24 h after injection. Like in the
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(Gly1, Ser3, Gln4, Thr6, Ala31, Aib32, Gln34)-PP on glutamate release
evoked by 15 mM KCl depolarization in hippocampal synaptosomes
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were injected with KA (10 mg/kg) and killed after 6 h, 24 h, 72 h or
30 days. The results represent the mean ± SEM of three to 14 inde-
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+++p < 0.001: Bonferroni’s post-test, statistical significance when
compared with 6 h; ###p < 0.001: Bonferroni’s post-test, statistical
significance when compared with 24 h; §p < 0.05, §§§p < 0.001:
Bonferroni’s post-test, statistical significance when compared with
72 h.
120 6 h
24 h
100
80
60
40
KC
l-e
vo
ke
d 
gl
u 
re
le
as
e 
(%
 of
 co
ntr
ol)
20
0
Control +
** **
**
**
+
++
++
300 nM NPY13-36
1 µM NPY
Fig. 2 Quantitative analysis of the effect of 300 nM NPY13-36 or 1 lM
NPY on glutamate release evoked by 15 mM KCl depolarization in
hippocampal synaptosomes obtained from rats injected with saline
(0.9% NaCl) and killed after 6 h or 24 h. The results represent the
mean ± SEM of three to nine independent experiments, in different
synaptosomal preparations. **p < 0.01: Bonferroni’s post-test, statis-
tical significance when compared with 6 h or 24 h control.
166 A. P. Silva et al.
 2005 International Society for Neurochemistry, J. Neurochem. (2005) 93, 163–170
control non-injected rats, we observed that in the presence of
300 nM NPY13-36 (Fig. 2), glutamate release was inhibited
after 6 h or 24 h (62.0 ± 5.9% or 59.2 ± 1.4% of control,
respectively), as well as in the presence of 1 lM NPY
(Fig. 2) (67.7 ± 2.9% and 62.1 ± 1.7% control, respect-
ively). These results suggest that the loss of inhibition
mediated by NPY13-36 or NPY in rats injected with kainate
and killed after 6 h is due to the epileptic stage and not to
possible stress induced by the injection itself.
Variation of NPY levels in the epileptic hippocampus
The NPY content of synaptosomes prepared from dentate
gyrus, CA3 and CA1 hippocampal synaptosomes from
control and epileptic rats (killed 24 h and 30 days after KA
injection) was determined, as described in Materials and
methods. We observed that in non-epileptic animals the NPY
content in synaptosomes from the dentate gyrus was higher
(271.5 ± 20.4 fM NPY/mg protein) compared with the CA1
and CA3 subregions (144.8 ± 10.9 and 129.3 ± 26.6 fM
NPY/mg protein, respectively) (Fig. 3a). Moreover, we
observed that the NPY content in dentate gyrus obtained
from epileptic rats killed 24 h after kainate injection
increased significantly (444.2 ± 55.1 fM NPY/mg protein)
(Fig. 3a). In the CA1 subregion, the NPY content decreased
in epileptic rats (68.4 ± 8.7 fM NPY/mg protein) whereas in
the CA3 subregion, the NPY levels remained similar to those
observed in the non-epileptic condition (124.4 ± 24.0 fM
NPY/mg protein) (Fig. 3a). However, in synaptosomes
obtained from rats killed 30 days after KA injection, we
observed increased levels of NPY in all hippocampal
subregions (dentate gyrus, 427.1 ± 15.0; CA3,
210.0 ± 10.9 and CA1, 235.3 ± 20.6 fM NPY/mg protein)
when compared with the non-epileptic values of the same
subregions (138.6 ± 15.0, 76.1 ± 12.4 and 79.3 ± 8.1 fM
NPY/mg protein, respectively) (Fig. 3b).
With regard to the results described above, we observed an
increased level of NPY (Fig. 3b) in the chronic epileptic
hippocampus but simultaneously, a diminished functional
effect of NPY in inhibiting the release of glutamate (Fig. 1d).
In an attempt to understand these apparent contradictory
findings, we decided to investigate a putative basal effect of
NPY in inhibiting the KCl-evoked release of glutamate from
synaptosomes isolated from the epileptic rat hippocampus.
We therefore measured the KCl-evoked release of glutamate
in the presence of the Y1, Y2 or Y5 receptor antagonists
(1 lM BIBP3226, 1 lM BIIE0246 or 1 lM L-152 804,
respectively). A potentiation of glutamate release was
observed only in the presence of the Y2 receptor antagonist
(133.0 ± 3.5% of control) (Fig. 4). We also performed the
same experiments in non-epileptic rats and found that none
of the antagonists had an effect by themselves on KCl-
evoked glutamate release (data not shown). Moreover, in
agreement with the effect of BIIE0246 (Fig. 4), we also
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observed an increase in Y2 receptor mRNA levels in the
hippocampus of epileptic rats compared with control non-
injected animals (827.8% of control) (Figs 5a and b).
Discussion
It is known that NPY receptors modulate the release of
glutamate in the hippocampus (Greber et al. 1994; Qian
et al. 1997; Whittaker et al. 1999; Silva et al. 2001) and that
the inhibition caused by NPY is partially mediated by the
activation of the Y2 receptor subtype, despite the simulta-
neous presence of Y1 and Y5 receptors in the hippocampus
(Silva et al. 2003a). In this study, we demonstrate that in
different stages of the epileptogenic process following
intraperitoneal injection of rats with KA the ability to
modulate the release of glutamate through the activation of
NPY receptors is changed. We suggest that in the acute phase
of epilepsy (6–24 h post-injection), a transient loss of NPY-
mediated inhibition of glutamate release may be causally
associated with hyperexcitability of the hippocampal neur-
onal network and seizure activity. Interestingly, following the
acute phase (72 h post-injection), an adaptation of the
NPYergic modulation of glutamate release was identified
and the inhibitory properties of NPY on glutamate release
were again close to control levels.
There is considerable evidence suggesting that the plastic
changes in NPY receptors (Vezzani et al. 1999) and the
functional and morphological alterations in peptidergic neu-
rones found in epileptic brain tissue (Schwarzeret al. 1996) are
mediated by glutamate release during seizures. Ro¨der et al.
(1996) showed that in the chronic period of epilepsy 7–30 days
after KA treatment, NPY Y2 receptor binding dropped below
control except in the hilus of dentate gyrus where it remained
elevated. Moreover, following seizures, changes in Y1-R
mRNA in the hippocampus are widespread but rapid and
transient, whereas there is a major increase in Y2-R mRNA
expression and a rapid and transient increase inY5-RmRNA in
the dentate granule cell layer (Kopp et al. 1999). However,
others have suggested a down-regulation of Y5 receptor in
KA-treated rats and kindledrats (Bregola et al. 2000). The
differences that we observed on the modulation of glutamate
release by NPY receptor activation could also be due to a
variation of protein expression in nerve terminals. We also
show that the modulation of glutamate release following
activation of the Y2 receptor subtype is similar to that activated
with the endogenous peptide, so it may be expected, as in non-
epileptic rats (Silva et al. 2003a), that NPY inhibits glutamate
release by preferentially activating Y2 receptors rather than Y1
andY5 receptors. Despite the strong evidence associatingNPY
receptor modulation of glutamate efflux to the epilepsy stage,
we should also consider the neurodegenerative processes that
occur under such conditions. Borges et al. (2004) recently
showed that after pilocarpine-induced status epilepticus in
mice, most hilar neurones died and NPY immunoreactivity
appeared in the dentate inner molecular layer, indicative of
mossy fibre sprouting. Moreover, we have previously shown
(Silva et al. 2003b) that under excitotoxic conditions, the
activation of NPY receptors has a neuroprotective effect.
The higher levels of NPY in the dentate gyrus compared
with the CA1 and CA3 subregions may result in a higher
presynaptic inhibition of glutamate release, probably through
the activation of Y2 receptors. Indeed, we have previously
shown that selective Y1, Y2 or Y5 receptor activation
significantly inhibits glutamate release in rat dentate gyrus
(Silva et al. 2001, 2003a). Klapstein and Colmers (1993)
showed that NPY inhibited excitatory postsynaptic potentials
(EPSPs) evoked in CA1 pyramidal cells from either stratum
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Fig. 5 (a) Total hippocampal RNA was subjected to RT-PCR analysis
for determination of NPY Y2 (318 bp) and actin (427 bp) mRNA levels.
(b) Quantification of hippocampal NPY Y2 mRNA levels in control
versus epileptic rats injected with 10 mg/kg kainate and killed after
30 days. **p < 0.01: Dunnett’s post-test, statistical significance when
compared with control (non-epileptic rats).
Table 1 Absolute values of KCl-evoked glutamate release (nM glutamate/mg protein/min) in the presence of the Y1, Y2, Y5 receptor agonist or
NPY, measured in synaptosomes obtained from non-epileptic rats or from epileptic rats injected with kainate (10 mg/kg) and killed after 6 h, 24 h,
72 h and 30 days. The results represent the mean ± SEM of three to 14 independent experiments, in different synaptosomal preparations
Y1 R agonist Y2 R agonist Y5 R agonist NPY
Non-epileptic 0.67 ± 0.07 0.58 ± 0.05 0.76 ± 0.07 0.60 ± 0.1
6 h 0.79 ± 0.07 0.96 ± 0.05 0.69 ± 0.06 1.1 ± 0.09
24 h 1.02 ± 0.09 0.68 ± 0.03 0.88 ± 0.05 0.58 ± 0.01
72 h 0.47 ± 0.08 0.47 ± 0.09 0.46 ± 0.09 0.40 ± 0.03
30 days 0.90 ± 0.01 0.89 ± 0.03 0.70 ± 0.07 0.93 ± 0.07
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radiatum or oriens, and also at mossy fibre-CA3, stratum
oriens-CA3 and CA3-CA3. By contrast, no inhibitory effect
was observed in EPSPs evoked in dentate granule cells from
either perforant path or commissural inputs. However,
neurochemical studies have already suggested that NPY is
abundantly expressed in the dentate gyrus in rodent models
of epilepsy and in the epileptic human (Greber et al. 1994;
Schwarzer et al. 1998). Others have shown that NPY inhibits
KCl-induced glutamate release in rat dentate gyrus synapto-
somes (Whittaker et al. 1999) and in the epileptic human
dentate gyrus (Patrylo et al. 1999). However, as in glutamate
release studies, we have also observed different variations in
NPY levels depending on the time elapsed after KA
injection. At 30 days post-injection, there was an increase
in NPY levels not only in the dentate gyrus but also in the
CA1 and CA3 subregions, compared with non-epileptic
animals. Moreover, Causing et al. (1996) showed an increase
in NPY mRNA levels in neurones of the ipsilateral and
contralateral dentate gyrus and Ammon’s Horn after inter-
mittent excitatory stimulation; NPY mRNA levels peaked at
4–24 h and had returned to baseline by 48 h post-stimula-
tion.
Taken together, the results obtained in synaptosomes
isolated 30 days after KA injection show that there is a
marked decrease in the inhibition of glutamate release due to
the activation of Y2 receptors and a simultaneous increase in
NPY levels. These apparently contradictory results were
better understood following our observation of a robust
increase in the expression of Y2 receptor mRNA and an
increase in KCl-evoked release of glutamate by blocking Y2
receptors. These results suggest that endogenous NPY
inhibits glutamate release through Y2 receptors under chronic
epileptic conditions. Again, a very relevant role for Y2
receptors in mediating the effects of NPY was identified. In
accordance, Ro¨der et al. (1996) showed that the increase in
Y2 receptor binding in the hilus of the dentate gyrus is
associated with enhanced NPY release after kainate injection.
In conclusion, our data support the hypothesis that NPY
can act as an endogenous neuromodulator that may limit
hyperexcitability in a rodent model of epilepsy, since NPY
levels and the expression of Y2 receptor mRNA are up-
regulated and the modulation of glutamate release through
NPY receptors is modified in KA-induced epilepsy. These
compensatory changes in the NPYergic system in the
epileptic hippocampus may play an important role in the
control of pathological excitability. Taken together, these
findings may suggest that overexpression of NPY and Y2
receptors may represent an important adaptation mechanism
in the epileptogenic process.
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